Table 1

EC0746 anti-arthritis activity in comparison with methotrexate and etanercept

Treatment

Dose

Frequency

Inhibition in paw edema (%)a

Splenomegalyb

Body weight change (%)c


Control

-

-

0

117 ± 22

-16 ± 1

EC0746 (s.c.)

25 nmol/kg

Biweekly

0 ± 25d

73 ± 8e

-17 ± 1

100 nmol/kg

Biweekly

35 ± 11d

52 ± 13e

-14 ± 1

250 nmol/kg

Biweekly

91 ± 4d

25 ± 6e

-0.5 ± 3

500 nmol/kg

Biweekly

91 ± 9

37 ± 7

0.4 ± 4

1,000 nmol/kg

Once weekly

72 ± 12

39 ± 5

-7 ± 3

MTX (p.o.)

250 nmol/kg

Biweekly

70 ± 5

42 ± 17

-14 ± 2

1,650 nmol/kg

Once weekly

47 ± 10f

-

-10 ± 2

MTX (s.c.)

250 nmol/kg

Biweekly

78 ± 10

24 ± 3

-2 ± 4

1,650 nmol/kg

Once weekly

63 ± 13f

-

-7 ± 8

Etanercept (s.c.)

10 mg/kg

Every 3 days

46 ± 9f

42 ± 7

-15 ± 2


Rats with adjuvant arthritis were treated at disease onset (10 days post arthritis induction) with EC0746, methotrexate (MTX), and etanercept at indicated doses, dosing routes, and dosing frequencies. s.c., subcutaneously; p.o., per orally. aInhibition in paw edema is calculated based on paw weight on day 24: 100 × (arthritic control - treated)/(arthritic control - healthy). bSplenomegaly is defined as the percentage increase in spleen weight relative to the spleen weights of healthy rats. cOn day 24 relative to body weight on the first day of treatment (day 10). Linear regression analysis: dR2 = 1.00 (paw) and eR2 = 0.99 (spleen). fCalculated based on arthritis scores on day 24 (paw weights were not obtained).

Lu et al. Arthritis Research & Therapy 2011 13:R56   doi:10.1186/ar3304

Open Data